Tumor Markers for Seminoma
For seminoma, measure β-hCG (beta-human chorionic gonadotropin) and LDH (lactate dehydrogenase) before orchiectomy, and continue monitoring β-hCG and AFP (alpha-fetoprotein) post-treatment in advanced disease—but critically, AFP should never be elevated in pure seminoma, and its elevation indicates mixed germ cell tumor requiring reclassification as nonseminomatous disease. 1
Key Tumor Markers and Their Significance
Primary Markers
- β-hCG: Can be elevated in pure seminoma (15-20% of cases) 2
- LDH: May be elevated in seminoma as a nonspecific tumor mass marker 1, 3
- AFP: Never produced by pure seminoma cells—any elevation above normal indicates nonseminomatous elements and requires reclassification as mixed germ cell tumor 1
Critical Diagnostic Point
A significantly elevated AFP in a patient with histopathologic diagnosis of "pure seminoma" definitively establishes the presence of nonseminomatous components, overriding the pathology report. This is because seminoma cells are biologically incapable of producing AFP. 1
Clinical Application by Disease Stage
Pre-Orchiectomy
- Measure AFP and β-hCG before diagnostic orchiectomy to establish baseline and aid post-operative interpretation 1
- Normal markers do not rule out testicular neoplasm or eliminate need for orchiectomy 1
Post-Orchiectomy Monitoring
For patients with pre-orchiectomy elevations:
- Measure post-orchiectomy β-hCG and/or LDH if they were elevated pre-operatively 1
- Do not use these post-orchiectomy levels for staging or prognosis in metastatic disease 1
Stage I Seminoma (Localized Disease)
The ASCO guidelines recommend AGAINST routine tumor marker surveillance for stage I seminoma 1. This recommendation is supported by research showing that in 527 patients with stage I seminoma, only 1 of 65 relapses was detected by elevated markers before imaging or physical exam findings, and this did not affect treatment or outcome 4.
Advanced Seminoma (Stage II-III)
Measure β-hCG and AFP at each surveillance visit after completing treatment for advanced seminoma 1:
Surveillance schedule:
- Year 1: Every 2-4 months
- Year 2: Every 3-4 months
- Years 3-4: Every 4-6 months
- Year 5+: Annually for at least 10 years 1
During Active Treatment
Do not use tumor markers to monitor treatment response during chemotherapy or radiation 1. However, measure β-hCG and AFP when treatment concludes—rising markers soon after therapy indicate progressive disease requiring salvage chemotherapy 1
Important Caveats and Pitfalls
False Positives for β-hCG
Mildly elevated β-hCG (generally <20 IU/L) requires careful interpretation, as hypogonadism and cannabis use can cause false-positive results 3. Further workup should be performed before initiating treatment based solely on mild β-hCG elevation.
LDH Limitations
Do not base treatment decisions on LDH elevation alone without corroborating evidence of progression 1. LDH has a high false-positive rate compared to AFP and β-hCG 1. While β-hCG and LDH may be elevated in seminoma, these levels alone should not be used to stage or risk-stratify patients with pure seminoma 3.
AFP Interpretation
- AFP <20 ng/mL: Mildly elevated, non-rising AFP may not indicate germ cell tumor; decisions should not be based solely on these values 3
- AFP >20 ng/mL: More highly elevated levels generally indicate nonseminomatous tumor elements and warrant reclassification 3
Rationale for Advanced Disease Monitoring
Approximately half of patients with seminoma who relapse after chemotherapy have elevated β-hCG 1. Additionally, patients initially diagnosed with "pure seminoma" may actually have occult mixed germ cell tumor, which can manifest as elevated AFP at relapse 1. While measuring AFP in these patients has low yield, it may enable earlier diagnosis of relapse 1.
The guidelines emphasize that tumor marker surveillance should not be the sole monitoring method—imaging with CT remains essential as part of comprehensive surveillance 1.